Long-term Remote Ischemic Preconditioning Improves Myocardial Perfusion and Prognosis of Patients After CABG
L-RIPC-CABG
1 other identifier
interventional
210
1 country
1
Brief Summary
Remote Ischemic preconditioning (RIPC) has been reported to improve myocardial microcirculation, promote collateral circulation recruitment, and improve myocardial perfusion in patients.Two large randomized controlled trials demonstrated a perioperative cardioprotective effect of RIPC (reduced troponin levels), but did not find that a single preoperative RIPC improved long-term outcomes of coronary artery bypass grafting(CABG).The effect of a single RIPC before CABG may be too short. This study aims to investigate whether long-term RIPC improved myocardial perfusion in patients 3 months and 6 months after CABG surgery , and to detect changes in blood vascular endothelial growth factor, Nitrc Oxide, adenosine,and Endothelin-1, and to observe MACCE event rates at 12 months.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for not_applicable
Started Mar 2021
Longer than P75 for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
February 4, 2021
CompletedFirst Posted
Study publicly available on registry
March 3, 2021
CompletedStudy Start
First participant enrolled
March 10, 2021
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 1, 2025
CompletedStudy Completion
Last participant's last visit for all outcomes
December 1, 2026
ExpectedSeptember 18, 2025
September 1, 2025
4.7 years
February 4, 2021
September 12, 2025
Conditions
Outcome Measures
Primary Outcomes (4)
Change of MBF by SPECT
Myocardial perfusion was evaluated by Single Photon Emission Computed Tomography(SPECT): myocardial blood flow(MBF)
3 months
Change of MPR by SPECT
Myocardial perfusion was evaluated by Single Photon Emission Computed Tomography(SPECT): myocardial perfusion reserve(MPR)
3 months
Change of MBF by CE
Myocardial perfusion was evaluated by contrast echocardiography(CE): myocardial blood flow(MBF)
3 months
Change of MPR by CE
Myocardial perfusion was evaluated by contrast echocardiography(CE): myocardial perfusion reserve(MPR)
3 months
Secondary Outcomes (15)
MBF by SPECT
1 weeks
MPR by SPECT
1 weeks
MBF by CE
1 weeks
MPR by CE
1 weeks
Rate of major adverse cardiovascular and cerebrovascular events
12 months
- +10 more secondary outcomes
Study Arms (3)
Experimental Group 1
EXPERIMENTALRoutine treatment + interventions:The patient underwent one RIPC (Four five-minute cycles of upper limb ischaemia and Four five-minute pauses using a blood pressure cuff air vehicle to 200 mmHg) before surgery, then normal surgery, and RIPC was performed on the second day and Once RIPC/day after CABG for one year.
Experimental Group 2
EXPERIMENTALRoutine treatment + interventions:Patients underwent a RIPC before surgery, and then normal medical procedures were performed with no additional intervention.
Control group
NO INTERVENTIONroutine treatment, no RIPC
Interventions
Four five-minute cycles of upper limb ischaemia and Four five-minute pauses using a blood pressure cuff inflated to 200 mmHg.
Eligibility Criteria
You may qualify if:
- Three coronary artery lesions, CABG surgery was planned
You may not qualify if:
- The patients could not tolerate ripc;
- peripheral vascular disease affecting upper limbs
- Acute myocardial infarction complicated with cardiogenic shock,in recent 30 days,
- Emergency cases
- Severe structural heart disease and severe arrhythmia ;
- The uncontrolled systolic blood pressure and diastolic blood pressure of severe hypertension were 180 mmHg and 120 mmHg respectively;
- Severe liver, renal and pulmonary disease
- Mental disorder can't cooperate;
- Inability to give informed consent;
- Patients on glibenclamide or nicorandil, as these medications may interfere with RIC
- pregnant;
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Fuwai central China cardiovascular Hospital
Zhengzhou, Henan, China
Related Publications (4)
Hausenloy DJ, Yellon DM. Remote ischaemic preconditioning: underlying mechanisms and clinical application. Cardiovasc Res. 2008 Aug 1;79(3):377-86. doi: 10.1093/cvr/cvn114. Epub 2008 May 2.
PMID: 18456674BACKGROUNDLau JK, Roy P, Javadzadegan A, Moshfegh A, Fearon WF, Ng M, Lowe H, Brieger D, Kritharides L, Yong AS. Remote Ischemic Preconditioning Acutely Improves Coronary Microcirculatory Function. J Am Heart Assoc. 2018 Oct 2;7(19):e009058. doi: 10.1161/JAHA.118.009058.
PMID: 30371329BACKGROUNDMeybohm P, Bein B, Brosteanu O, Cremer J, Gruenewald M, Stoppe C, Coburn M, Schaelte G, Boning A, Niemann B, Roesner J, Kletzin F, Strouhal U, Reyher C, Laufenberg-Feldmann R, Ferner M, Brandes IF, Bauer M, Stehr SN, Kortgen A, Wittmann M, Baumgarten G, Meyer-Treschan T, Kienbaum P, Heringlake M, Schon J, Sander M, Treskatsch S, Smul T, Wolwender E, Schilling T, Fuernau G, Hasenclever D, Zacharowski K; RIPHeart Study Collaborators. A Multicenter Trial of Remote Ischemic Preconditioning for Heart Surgery. N Engl J Med. 2015 Oct 8;373(15):1397-407. doi: 10.1056/NEJMoa1413579. Epub 2015 Oct 5.
PMID: 26436208BACKGROUNDHausenloy DJ, Candilio L, Evans R, Ariti C, Jenkins DP, Kolvekar S, Knight R, Kunst G, Laing C, Nicholas J, Pepper J, Robertson S, Xenou M, Clayton T, Yellon DM; ERICCA Trial Investigators. Remote Ischemic Preconditioning and Outcomes of Cardiac Surgery. N Engl J Med. 2015 Oct 8;373(15):1408-17. doi: 10.1056/NEJMoa1413534. Epub 2015 Oct 5.
PMID: 26436207BACKGROUND
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Muwei Li, Ph.D
Fuwai central China cardiovascular hospotial
- PRINCIPAL INVESTIGATOR
Zhaoyun Cheng, Ph.D
Fuwai central China cardiovascular hospotial
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- NONE
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
February 4, 2021
First Posted
March 3, 2021
Study Start
March 10, 2021
Primary Completion
December 1, 2025
Study Completion (Estimated)
December 1, 2026
Last Updated
September 18, 2025
Record last verified: 2025-09
Data Sharing
- IPD Sharing
- Will not share
One year after the end of the trial, other outside investigators could access the original data on reasonable requests